Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

6.050 -0.030 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutic Com

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sage Therapeutics's Earnings: A Preview
Via Benzinga
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... 
Via Benzinga
Topics Workforce
Exposures Layoff
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. 
Via Benzinga
The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts
Via Benzinga
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
Via Benzinga
Analyst Expectations For Sage Therapeutics's Future
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February... 
Via Benzinga
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps. 
Via Benzinga
19 Analysts Have This To Say About Sage Therapeutics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Via Benzinga
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
Via Benzinga
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with! 
Via InvestorPlace
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Sage Therapeutics Reports Phase 2 Huntington's Data
On Tuesday before the market opened, Sage Therapeutics announced findings regarding Huntington's Disease (HD) based upon topline results from the Phase 2 SURVEYOR Study. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Sunday, June 2
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of May 27 through June 2, 2024. 
Via Talk Markets
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.